Olema Pharmaceuticals director sells 25,000 shares

Olema Pharmaceuticals director Cyrus Harmon reported selling a total of 25,000 shares of common stock in open-market or private transactions on July 23 and 24, 2026, at weighted average prices of $11.579 and $11.714 per share, respectively.

Rhea-AI Filing Summary

Olema Pharmaceuticals director Cyrus Harmon reported selling a total of 25,000 shares of common stock in open-market or private transactions on July 23 and 24, 2026, at weighted average prices of $11.579 and $11.714 per share, respectively. An additional 117,028 shares are reported as held indirectly by Harmon Family Investors LLC, where Harmon is the manager.

Insider Trade Summary

Net Seller: 25,000 shares

Net Sell 3 txns

Insider Harmon Cyrus

Role Director

Sold 25,000 shs ($291K)

Type	Security	Shares	Price	Value
Sale	Common Stock F2	12,500	$11.714	$146K
Sale	Common Stock F1	12,500	$11.579	$145K
holding	Common Stock F3	--	--	--

Holdings After Transaction: Common Stock — 702,770 shares (Direct); Common Stock — 117,028 shares (Indirect, See Footnote)

Footnotes (3)

1. F1. The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
2. F2. The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

Key Figures

Sale on 2026-07-23: 12,500 shares at $11.579 Sale on 2026-07-24: 12,500 shares at $11.714 Total shares sold: 25,000 shares +3 more

6 metrics

Sale on 2026-07-23 12,500 shares at $11.579 Open-market or private sale of common stock on July 23, 2026

Sale on 2026-07-24 12,500 shares at $11.714 Open-market or private sale of common stock on July 24, 2026

Total shares sold 25,000 shares Aggregate of two reported sales on July 23–24, 2026

Indirectly held shares 117,028 shares Held by Harmon Family Investors LLC with Cyrus Harmon as manager

Price range 2026-07-23 $11.52–$11.675 Range of individual sale prices on July 23, 2026

Price range 2026-07-24 $11.70–$11.775 Range of individual sale prices on July 24, 2026

Key Terms

weighted average sale price, open market or private transaction, Harmon Family Investors LLC

3 terms

weighted average sale price financial

"The weighted average sale price for the transaction reported was $11.579,"

open market or private transaction financial

"Sale in open market or private transaction"

Harmon Family Investors LLC financial

"The shares are held by the Harmon Family Investors LLC, of which"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Olema Pharmaceuticals (OLMA) report for Cyrus Harmon?

Cyrus Harmon, a director of Olema Pharmaceuticals, sold 25,000 shares of common stock in two transactions on July 23 and 24, 2026. Both were reported as open-market or private sales of Olema common stock.

At what prices did Cyrus Harmon sell Olema Pharmaceuticals (OLMA) shares?

The reported weighted average sale prices were $11.579 per share on July 23, 2026, and $11.714 per share on July 24, 2026. Footnotes state each trade occurred within specified intraday price ranges.

How many Olema Pharmaceuticals (OLMA) shares did Cyrus Harmon sell in each transaction?

Cyrus Harmon sold 12,500 shares of Olema common stock on July 23, 2026, and another 12,500 shares on July 24, 2026. Together, the transactions total 25,000 shares sold.

What indirect holdings in Olema Pharmaceuticals (OLMA) are reported for Cyrus Harmon?

The filing reports 117,028 Olema shares held indirectly by Harmon Family Investors LLC. A footnote explains that the LLC holds the shares and that Cyrus Harmon serves as its manager.

Were Cyrus Harmon’s Olema Pharmaceuticals (OLMA) trades under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox is not marked as affirmative, indicating the reported sales were not designated as made under a Rule 10b5-1 trading plan in this filing.

How is the sale price information for Olema Pharmaceuticals (OLMA) insider trades presented?

The per-share prices reflect weighted average sale prices of $11.579 and $11.714. Footnotes state detailed breakdowns of shares sold at each individual price within the reported ranges are available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/27/2026 - 07:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harmon Cyrus

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CALIFORNIA 94103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/23/2026		S		12,500	D	$11.579(1)	715,270	D
Common Stock	07/24/2026		S		12,500	D	$11.714(2)	702,770	D
Common Stock								117,028	I(3)	See Footnote

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

2. The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

	/s/ Shawnte Mitchell, Attorney-in-Fact	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)